ARTICLE | Clinical News
FDA places clinical hold on Ph I of Epizyme's tazemetostat
April 27, 2018 7:57 PM UTC
Epizyme Inc. (NASDAQ:EPZM) said FDA placed a partial clinical hold on tazemetostat (E7438, EPZ-6438) following a report of a patient who developed secondary T cell lymphoma during a Phase I pediatric trial of the selective inhibitor of enhancer of zeste homolog 2 (EZH2).
The hold suspends new enrollment in U.S. clinical trials of tazemetostat. Patients already enrolled who have not experienced disease progression may continue to receive tazemetostat...
BCIQ Company Profiles
BCIQ Target Profiles